Crinetics appoints Jeff Knight as COO with $400k salary, 40% bonus, and 160k-share option grant

Crinetics Pharmaceuticals, Inc.

Appointment effective August 30, 2021; Knight most recently SVP at Poseida Therapeutics.
Annual base salary of $400,000 with target annual incentive bonus of 40% of base.
Received option to purchase 160,000 shares vesting 25% on Aug 30, 2022 then monthly over 3 years.
Sign-on bonus of $40,000 in connection with commencement of employment.
Knight brings over 25 years of clinical drug development experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeff Knight

Chief Operating Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2021-08-30
Filed: September 2, 2021, 7:59 PM ET

On September 2, 2021, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Jeff Knight as the Company’s Chief Operating Officer, which was effective as of August 30, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Knight was appointed as Chief Operating Officer at Crinetics Pharmaceuticals, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On September 2, 2021, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Jeff Knight as the Company’s Chief Operating Officer, which was effective as of August 30, 2021.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-046992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.